MTCH2 and neoplasm: Considering the synergistic anti‐tumor effects of MTCH2 silencing and ferroptosis‐inducing agents in CRC cells, we next sought to investigate whether MTCH2 could affect sorafenib treatment of CRC liver metastasis.